GSK PLC Sponsored ADR $GSK Shares Purchased by NewEdge Advisors LLC

NewEdge Advisors LLC increased its position in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 842.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 953,574 shares of the pharmaceutical company’s stock after purchasing an additional 852,437 shares during the quarter. NewEdge Advisors LLC’s holdings in GSK were worth $49,986,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. IHT Wealth Management LLC lifted its holdings in GSK by 1.3% in the 4th quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock valued at $736,000 after purchasing an additional 188 shares in the last quarter. Bogart Wealth LLC grew its holdings in shares of GSK by 15.3% during the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after buying an additional 200 shares in the last quarter. Natural Investments LLC grew its holdings in shares of GSK by 2.8% during the second quarter. Natural Investments LLC now owns 7,726 shares of the pharmaceutical company’s stock worth $405,000 after buying an additional 211 shares in the last quarter. HF Advisory Group LLC raised its position in shares of GSK by 3.5% in the second quarter. HF Advisory Group LLC now owns 7,578 shares of the pharmaceutical company’s stock valued at $397,000 after buying an additional 259 shares during the last quarter. Finally, NBT Bank N A NY raised its position in shares of GSK by 1.9% in the first quarter. NBT Bank N A NY now owns 16,568 shares of the pharmaceutical company’s stock valued at $914,000 after buying an additional 315 shares during the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Price Performance

Shares of GSK stock opened at $48.66 on Thursday. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The firm’s 50-day moving average is $51.51 and its two-hundred day moving average is $52.91. GSK PLC Sponsored ADR has a 12 month low of $39.29 and a 12 month high of $61.69. The company has a market capitalization of $98.42 billion, a PE ratio of 15.22, a price-to-earnings-growth ratio of 2.03 and a beta of 0.35.

GSK (NYSE:GSK) last posted its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.02 billion. During the same quarter in the prior year, the company posted $0.47 EPS. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts predict that GSK PLC Sponsored ADR will post 4.81 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.4515 per share. This represents a $1.81 annualized dividend and a yield of 3.7%. This is a positive change from GSK’s previous quarterly dividend of $0.44. The ex-dividend date of this dividend is Friday, August 14th. GSK’s payout ratio is 55.63%.

Analyst Ratings Changes

GSK has been the topic of a number of recent research reports. Royal Bank Of Canada started coverage on shares of GSK in a research report on Tuesday. They set a “sector perform” rating on the stock. Wall Street Zen lowered shares of GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. HSBC upgraded GSK from a “reduce” rating to a “hold” rating in a report on Monday, July 6th. Jefferies Financial Group raised GSK to a “strong-buy” rating in a report on Friday, July 17th. Finally, Citigroup started coverage on GSK in a research report on Friday, July 24th. They set a “neutral” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $53.00.

GSK Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.